Cerberus Therapeutics Appoints Dr. Michael Hodges to its Scientific Advisory Board

CAMBRIDGE, Mass., May 15, 2023 – Cerberus Therapeutics, Inc., an early-stage biotechnology company focused on development of proprietary nanobody-based platforms to create novel immunotherapeutics, today announced the appointment of Dr. Michael Hodges, MD, an infectious disease clinician and RNA medicines drug development executive with 30 years of experience within the biopharmaceutical industry, to its Scientific Advisory Board.

“Michael has extensive experiences in the infectious diseases field, from both business and regulatory perspectives, with multiple drugs approved under his leadership in his prior pharmaceutical executive positions,” said Novalia Pishesha, Ph.D., Chief Executive Officer and Co-Founder of Cerberus Therapeutics. “We look forward to working with Michael to advance Cerberus’ infectious diseases programs.”

Michael is a partner at Claris Ventures a biotechnology venture capital fund based in Turin (Italy) with the mission to unlock the full potential of the Italian R&D ecosystem. He was previously the CMO of Amplyx Pharmaceuticals, developing small molecule and monoclonal antibody drug treatments for life-threatening viral and fungal infections in immunocompromised patients. The company was acquired by Pfizer, Inc. Prior to Amplyx he was the CMO and head of drug development for Santaris A/S, developing RNA targeting drug treatments for chronic viral diseases, cancer, metabolic/lipid and eye diseases. The company was acquired by Hoffman-La Roche, AG.

Michael started his career in pharmaceutical medicines with Pfizer Global Research and Development where he worked on multiple infectious diseases and oncology development programs. Under his leadership two antifungal drugs where approved, VFEND® (voriconazole) and ERAXIS™ (anidulafungin).

Michael was a Non-Executive Director of F2G Ltd., an infectious disease biotechnology company from 2010-2014. He earned his M.D. (MBBS) and BSc. in Pharmacology, from the University of London, UK.

About Cerberus Therapeutics

Founded in 2021 by Novalia Pishesha, Ph.D., Prof. Hidde Ploegh, Ph.D. and Prof. Harvey Lodish, Ph.D., Cerberus Therapeutics’ nanobody-based technology comprises two distinct platforms: one that targets autoimmunity and one aimed at infectious disease. Leveraging the unique biochemical properties and excellent targeting capabilities of alpaca-derived nanobodies (variable domains of heavy chain-only antibodies), Cerberus’ technology has the potential to reset the immune system and have it rewire itself for therapeutic gain.

Cerberus Contact:
Xiaohong Sang